Thank you for your interest in the Innovations in Pre-exposure Prophylaxis (PrEP) for Respiratory Viruses program. Since the program is looking for innovations in delivery, biodistribution, and durability of PrEP approaches, teaming collaborations between diverse sets of innovators might be needed to achieve these goals.
Teaming
If you or your organization would like to explore collaborations with other potential applicants, please complete the form below. After a short vetting process, you will be contacted be VITAL, and your information will be added to the publicly accessible list below.
Please note that by publishing the teaming profiles list, neither VITAL nor BARDA is endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included. Additionally, completing the form does not constitute an application for the PrEP funding opportunity, but rather, provides you an opportunity to partner and collaborate with other potential applicants to strengthen the quality of the submission.
Submissions to the teaming profiles list are reviewed and updated periodically.
Contact
Organization
Relevant Technology
Potential for Teaming
InDevR offers a multiplexed, microarray-based analytics platform called VaxArray. VaxArray assays can be flexibly designed to simultaneously quantify dozens of analytes in a single assay with high ease of use and rapid times to result of ~1 hour. By printing antibodies in a microarray format, we can assess relative antigen binding for initial therapeutic antibody screening applications. Alternatively, by printing recombinant antigens or peptides, we can assess antibody binding to a variety of closely-related antigens. If potential therapeutic antibodies are being delivered as LNP-mRNAs, VaxArray can also be used to assess the quantity of the in vitro expressed antibody/antibodies. InDevR has been supporting influenza, COVID, pneumococcal conjugate, and other vaccine developers and manufacturers for over 15 years with numerous off the shelf kits. In addition, we offer full custom assay development services and have delivered on over 40 custom projects. Our VaxArray influenza NA assay is being utilized as an official release assay for identity testing, and our platform software is amenable to integration in 21 CFR part 11-regulated environments.
We would like to partner with responders to this call by developing custom assays that would fill an analytical gap for their development program that would be well-addressed with an easy to use, rapid, multiplexed VaxArray platform approach.
Jubilant HollisterStier LLC, (JHS) is a leading integrated contract manufacturer of parenteral products and ophthalmics. We are able to support manufacturing of multiple formats for sterile liquid/lyophilized vials, ampoules and sterile ophthalmic solutions and ointments. Located in Spokane, Washington, and Montreal, Quebec Canada JHS provides specialized manufacturing for pharmaceutical and biopharmaceutical products and offers a full range of other support, from process qualification through commercial release with final packaging and serialization services.
As one of the recipients of the U.S. Department of Health and Human Services’ (“HHS”) investments in the Industrial Base Expansion (“IBX”) program, JHS will double the capacity of the fill-finish site in Spokane, Washington by 2024 resulting in sterile injectable production of over 110 million units per year. The capabilities and technologies included in the expansion include:
Innovators without the capability of clinical and large scale manufacturing.
CHO Plus has developed technologies for engineering cells toward increasing and improving biologicals productivity such as monoclonal antibodies and viral vectors. We have demonstrated the ability to produce monoclonal antibodies at up to 13.5 grams/liter. We engineer CHO cells to contain up to 40-fold higher endoplasmic reticulum per cell and these cells are high producers. We can also engineer cells to contain much higher amounts of Golgi apparatus per cell. We believe we can increase sialic acid site occupancy from the common range of 60-80% to approximately 90%. Higher sialic acid is known to increase serum half-life. We can make YTE mutations in the Fc portion of the mAbs that have been shown to increase serum half-life and used in many licensed antibody therapeutics. The CHO Plus innovation will combine our high productivity cell lines to make higher sialic acid mAbs, YTE mutation mAbs, and mAbs that combine both.
CHO Plus’s expertise is cell engineering technology not respiratory product development. We seek a partner active in the respiratory therapeutics space to properly test—or to supervise the testing of—the mAbs we produce to measure long acting mAbs potential against influenza, or other high priority targets, with serum PK studies in humanized rodent models.
MucosaTec develops a long-acting monoclonal antibody platform targeting influenza virus and RSV as its initial focus. The platform is based on mAb conjugates, which enhance durability.
A potential partner supplies mAbs at large scales.
ARNAV biotech focuses on mRNA-based antiviral therapeutics against influenza virus.
We are looking for partners with drug delivery and especially nebulization of mRNA based therapeutics.
